These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 15644044)

  • 1. Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy.
    D'Souza R; Main J; Crossey M; Rosenberg W; Murray-Lyon IM; Hayward C; Foster GR
    Aliment Pharmacol Ther; 2005 Jan; 21(1):43-7. PubMed ID: 15644044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.
    Lee SS; Bain VG; Peltekian K; Krajden M; Yoshida EM; Deschenes M; Heathcote J; Bailey RJ; Simonyi S; Sherman M;
    Aliment Pharmacol Ther; 2006 Feb; 23(3):397-408. PubMed ID: 16422999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
    Borroni G; Andreoletti M; Casiraghi MA; Ceriani R; Guerzoni P; Omazzi B; Terreni N; Salerno F
    Aliment Pharmacol Ther; 2008 May; 27(9):790-7. PubMed ID: 18298638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
    Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
    Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.
    Tang KH; Herrmann E; Pachiadakis I; Paulon E; Tatman N; Zeuzem S; Naoumov NV
    Aliment Pharmacol Ther; 2008 May; 27(9):810-9. PubMed ID: 18221408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.
    Itose I; Kanto T; Inoue M; Miyazaki M; Miyatake H; Sakakibara M; Yakushijin T; Oze T; Hiramatsu N; Takehara T; Kasahara A; Katayama K; Kato M; Hayashi N
    J Med Virol; 2007 May; 79(5):511-21. PubMed ID: 17385691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
    J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
    Baker RD; Dee D; Baker SS
    J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
    Berg C; Goncales FL; Bernstein DE; Sette H; Rasenack J; Diago M; Jensen DM; Graham P; Cooksley G
    J Viral Hepat; 2006 Jul; 13(7):435-40. PubMed ID: 16792536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
    Diago M; Olveira A; Solá R; Romero-Gómez M; Moreno-Otero R; Pérez R; Salmerón J; Enríquez J; Planas R; Gavilán JC; Del Olmo J; Uribarrena R; Sillero C; Benítez A; Sánchez-Galdón S; Dalmau B; Eraña L; Montoro M; Portu J; Garijo JM; Barniol R; Domínguez A; Rota R; Olcoz JL; Antón M; Pamplona X; Casanovas T; Jiménez E; Huarte M; Díaz F; Sánchez-Ruano J; Orive M; Muñoz-Sánchez M; Roset M
    Aliment Pharmacol Ther; 2007 Apr; 25(8):899-906. PubMed ID: 17402993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.